Form 4: Ventyx Biosciences Chief Medical Officer Acquires Stock Options

Mark S. Forman, Chief Medical Officer of Ventyx Biosciences, Inc., reports the acquisition of stock options.

Summary

• Mark S. Forman, the Chief Medical Officer of Ventyx Biosciences, Inc., filed a Form 4 on August 13, 2024.
• The report details a transaction on August 12, 2024, where Forman acquired stock options for 350,000 shares of Ventyx Biosciences common stock at an exercise price of $1.95.
• These options vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting monthly thereafter, contingent upon continued service.

Sentiment

Score: 6

Explanation: The document itself is neutral, reporting a standard stock option grant. The sentiment is slightly positive as it indicates alignment of management with shareholder interests.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, aligning the executive's interests with those of the shareholders.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies, similar to practices at companies like Amgen, Gilead Sciences, and Biogen.
• Vesting schedules, such as the four-year vesting period with a one-year cliff, are also typical in the industry.

Stakeholder Impact

• The stock option grant aligns the interests of the Chief Medical Officer with those of the shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates